All updated as on -
Valued at $5.25 billion in 2022, the worldwide blood stream infection testing market is expected to expand at a CAGR of 9.3% between 2023 and 2030, increasing to $10.59 billion.
A blood stream infection is an infection that has spread into the blood and can be caused by bacteria, fungi, or any other type of organism. When a pathogen enters the bloodstream from any organ or tissue in the body, it quickly becomes systemic and causes disease. In order to determine what bacteria or other organisms are responsible for blood infections, blood stream infection testing is performed. Poor sanitation and hygiene practices contribute to the rapid spread of a variety of infectious diseases, posing a serious threat to human health in highly crowded places. Common symptoms of bloodstream infections include chills, a cold, fever, diarrhea, and vomiting, making a self-diagnosis difficult.
The market for testing for bloodstream infections was moderately affected by the COVID-19 pandemic. The purpose of this retrospective observational study was to determine the frequency and types of bloodstream infections experienced by COVID-19 patients treated at a tertiary care center in Jaipur, India. During the study period of 5 months, a total of 158 blood cultures were taken from inpatients who tested positive for COVID-19 at the hospital. Fifteen of these cultivars (9.4%) performed well.
Furthermore, the risk of healthcare-associated bloodstream infections has been raised due to the use of invasive medical procedures and devices in COVID-19 patients. A silver lining to the pandemic is that it has hastened the introduction of infection-prevention measures and highlighted the significance of reliable diagnostics. As a result, there is a growing need in the market for treatments for bloodstream infections to combat the difficulties caused by COVID-19. However, the risk of healthcare-associated bloodstream infections in COVID-19 patients has grown due to the use of invasive medical procedures and devices. A silver lining to the pandemic is that it has hastened the introduction of infection-prevention measures and highlighted the significance of reliable diagnostics. As a result, there is a growing need in the market for treatments for bloodstream infections to combat the difficulties caused by COVID-19.
The rising incidence of bloodstream infections around the world is anticipated to be a major growth driver for this industry. Bloodstream infections are a major source of illness and death around the world, according to the U.S. National Library of Medicine, the biggest medical library in the world. The rate of BSIs has increased to anywhere from 122 to 220 per 100,000 people annually. Rapid detection is essential, and technological advances in blood-borne illness testing are projected to fuel market expansion. Demand for bloodstream infection testing is expected to fuel revenue growth of the market due to the rising rates of bloodstream infections in the senior population, who are susceptible to infection due to reduced immunity.
As technology improves and automated systems like MALDI-TOF and DOT are launched, the high cost of ownership and high maintenance costs can hinder market development. Expensive testing techniques may be a further impediment to expanding markets. It is anticipated that the lack of insurance and reimbursement policies will also hinder the growth of the market. Healthcare facilities, hospitals, and diagnostic laboratories all offer services to check for infections in the bloodstream. The main goal of the examination is to identify the bacterium or organism responsible for the blood infection.
Market expansion is anticipated to be driven by the rising global awareness of infectious disorders including HIV, pneumonia, and cancer, all of which necessitate blood testing at regular intervals. The technical advances made by various market participants to improve the testing equipment also play a major role in driving the market expansion. The established market players are constantly upgrading technologies such multifunction automated machines to increase the quality of healthcare equipment offered to patients, and this is shown in the field of medical tools.
However, the market is hampered by the fact that less money is invested in developing nations, where there are fewer medical testing facilities and the cost of diagnosis is higher. Opportunities may arise throughout the projected period as a result of the introduction of new gadgets that are both cost-effective and simple to use. The market could face significant resistance from the strict regulatory environment and the rigorous reimbursement regulations.
Report Coverage
Global Blood Stream Infection Testing research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Blood Stream Infection Testing report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Blood Stream Infection Testing competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Blood Stream Infection Testing market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Blood Stream Infection Testing market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Blood Stream Infection Testing market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Abbott, BD, bioMérieux SA, Beckman Coulter, Inc., Babson Diagnostics, Diazyme Laboratories, Inc., Cepheid, Luminex Corporation, Accelerate Diagnostics, Inc., InBios International, Inc., Ortho Clinical Diagnostics, OpGen, Bruker, Grifols SA GmbH, AdvanDx, becton dickinson medical devices co. ltd., suzhou and Danaher among other.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Blood Stream Infection Testing market based on the below-mentioned segments:
Global Blood Stream Infection Testing Market, By Product
Instruments
Consumables
Software and Services
Global Blood Stream Infection Testing market, By Application
Bacterial
Fungal
Mycobacterial
Global Blood Stream Infection Testing Market, By End User
Hospitals
Independent Diagnostics Centers
Others
Global Blood Stream Infection Testing market, Regional Analysis
A blood stream infection is an infection that has spread into the blood and can be caused by bacteria, fungi, or any other type of organism. When a pathogen enters the bloodstream from any organ or tissue in the body, it quickly becomes systemic and causes disease. In order to determine what bacteria or other organisms are responsible for blood infections, blood stream infection testing is performed. Poor sanitation and hygiene practices contribute to the rapid spread of a variety of infectious diseases, posing a serious threat to human health in highly crowded places. Common symptoms of bloodstream infections include chills, a cold, fever, diarrhea, and vomiting, making a self-diagnosis difficult.
The market for testing for bloodstream infections was moderately affected by the COVID-19 pandemic. The purpose of this retrospective observational study was to determine the frequency and types of bloodstream infections experienced by COVID-19 patients treated at a tertiary care center in Jaipur, India. During the study period of 5 months, a total of 158 blood cultures were taken from inpatients who tested positive for COVID-19 at the hospital. Fifteen of these cultivars (9.4%) performed well.
Furthermore, the risk of healthcare-associated bloodstream infections has been raised due to the use of invasive medical procedures and devices in COVID-19 patients. A silver lining to the pandemic is that it has hastened the introduction of infection-prevention measures and highlighted the significance of reliable diagnostics. As a result, there is a growing need in the market for treatments for bloodstream infections to combat the difficulties caused by COVID-19. However, the risk of healthcare-associated bloodstream infections in COVID-19 patients has grown due to the use of invasive medical procedures and devices. A silver lining to the pandemic is that it has hastened the introduction of infection-prevention measures and highlighted the significance of reliable diagnostics. As a result, there is a growing need in the market for treatments for bloodstream infections to combat the difficulties caused by COVID-19.
The rising incidence of bloodstream infections around the world is anticipated to be a major growth driver for this industry. Bloodstream infections are a major source of illness and death around the world, according to the U.S. National Library of Medicine, the biggest medical library in the world. The rate of BSIs has increased to anywhere from 122 to 220 per 100,000 people annually. Rapid detection is essential, and technological advances in blood-borne illness testing are projected to fuel market expansion. Demand for bloodstream infection testing is expected to fuel revenue growth of the market due to the rising rates of bloodstream infections in the senior population, who are susceptible to infection due to reduced immunity.
As technology improves and automated systems like MALDI-TOF and DOT are launched, the high cost of ownership and high maintenance costs can hinder market development. Expensive testing techniques may be a further impediment to expanding markets. It is anticipated that the lack of insurance and reimbursement policies will also hinder the growth of the market. Healthcare facilities, hospitals, and diagnostic laboratories all offer services to check for infections in the bloodstream. The main goal of the examination is to identify the bacterium or organism responsible for the blood infection.
Market expansion is anticipated to be driven by the rising global awareness of infectious disorders including HIV, pneumonia, and cancer, all of which necessitate blood testing at regular intervals. The technical advances made by various market participants to improve the testing equipment also play a major role in driving the market expansion. The established market players are constantly upgrading technologies such multifunction automated machines to increase the quality of healthcare equipment offered to patients, and this is shown in the field of medical tools.
However, the market is hampered by the fact that less money is invested in developing nations, where there are fewer medical testing facilities and the cost of diagnosis is higher. Opportunities may arise throughout the projected period as a result of the introduction of new gadgets that are both cost-effective and simple to use. The market could face significant resistance from the strict regulatory environment and the rigorous reimbursement regulations.
Report Coverage
Global Blood Stream Infection Testing research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Blood Stream Infection Testing report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Blood Stream Infection Testing competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Blood Stream Infection Testing market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Abbott, BD, bioMérieux SA, Beckman Coulter, Inc., Babson Diagnostics, Diazyme Laboratories, Inc., Cepheid, Luminex Corporation, Accelerate Diagnostics, Inc., InBios International, Inc., Ortho Clinical Diagnostics, OpGen, Bruker, Grifols SA GmbH, AdvanDx, becton dickinson medical devices co. ltd., suzhou and Danaher among other. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Blood Stream Infection Testing Market from 2021 to 2030.
- Market Forecast for Blood Stream Infection Testing Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Blood Stream Infection Testing competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Blood Stream Infection Testing
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Blood Stream Infection Testing market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Blood Stream Infection Testing market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Abbott, BD, bioMérieux SA, Beckman Coulter, Inc., Babson Diagnostics, Diazyme Laboratories, Inc., Cepheid, Luminex Corporation, Accelerate Diagnostics, Inc., InBios International, Inc., Ortho Clinical Diagnostics, OpGen, Bruker, Grifols SA GmbH, AdvanDx, becton dickinson medical devices co. ltd., suzhou and Danaher among other.
Primary Target Market
- Market Players of Blood Stream Infection Testing
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Blood Stream Infection Testing market based on the below-mentioned segments:
Global Blood Stream Infection Testing Market, By Product
Instruments
Consumables
Software and Services
Global Blood Stream Infection Testing market, By Application
Bacterial
Fungal
Mycobacterial
Global Blood Stream Infection Testing Market, By End User
Hospitals
Independent Diagnostics Centers
Others
Global Blood Stream Infection Testing market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive blood stream infection testing market market research and competitor analysis for your business to help you develop more profound insights into the blood stream infection testing market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the blood stream infection testing market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.